sapacitabine
Small moleculeexperimental
Sapacitabine is a chemotherapeutic drug developed by US biotechnology firm Cyclacel currently undergoing clinical trials against leukemia. — Wikipedia
Clinical trial activity
8 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2006 (NCT00380653)
Timeline
Indications
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Cytotoxic. Interferes with DNA synthesis by introducing single-strand DNA breaks leading to arrest of the cell division cycle at G2 phase and development of double-strand DNA breaks.
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1- Mol. weight
- 490.65 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- WikipediaSapacitabine ↗
- ChEMBLCHEMBL2105681 ↗
Also known as
- 2'-c-cyano-2'-deoxy-1-arabinofuranosyl-n(4)-palmitoylcytosine
- cndac cpd
- cs-682
- cs-682
- cs-682
- cyc682
- cyc 682
- cyc-682
- cyc-682
- cyc-682
- sapacitabine
- sapacitabine
- sapacitabine
- sapacitabine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06679322 | Phase 2 | Oct 31, 2024 | Capital Medical University |
| NCT03641755 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2018 | AstraZeneca, Cyclacel Pharmaceuticals, Inc., Harvard University |
| NCT03358901 | Phase 1 | Dec 31, 2016 | Chinese Academy of Medical Sciences, Guangzhou Cellprotek Pharmaceutical Co., Ltd., Xiuhe Medical Technique Co.,Ltd. |
| NCT01253460 | Phase 2 | Jul 1, 2011 | Cyclacel Pharmaceuticals, Inc., National Cancer Institute (NCI), University of Texas at Houston |
| NCT00885963 | Phase 2 | Dec 1, 2008 | Cyclacel Pharmaceuticals, Inc., Rush University |
| NCT00590187 | Phase 2 | Dec 1, 2007 | Cyclacel Pharmaceuticals, Inc. |
| NCT00476554 | Phase 2 | Apr 1, 2007 | Cyclacel Pharmaceuticals, Inc. |
| NCT00380653 | Phase 1 | Jan 1, 2006 | Cyclacel Pharmaceuticals, Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | For profit | 6 | 4 | 2 | 2006 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2018 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Guangzhou Cellprotek Pharmaceutical Co., Ltd. | For profit | 1 | 1 | 1 | 2016 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2011 |
| Rush University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Xiuhe Medical Technique Co.,Ltd. | Government | 1 | 0 | 1 | 2016 |
10 organizations
Page 1 / 1